Our Science – Orentas Website
Rimas J. Orentas, Ph.D.
My interest is the immunotherapy of cancer. Bioinformatic approaches are being developed to identify antigenic targets that are uniquely or over-expressed on pediatric tumors and leukemias. To date this has primarily focused on gene expression profiling, but we are now incorporating next-generation sequencing technologies to more fully describe the landscape available for immune targeting.
Focusing on known targets (such as the antigens GD2, ALK, or CD22), as well as new targets we have identified, we then design unique binding sequences that can then be engineered into chimeric antigen receptors (CARs). T cells transduced with genetic vectors to express CARs are being evaluated for their potential in the adoptive immunotherapy of cancer. How best to engineer T lymphocytes to express CARs and the biology of genetically engineered T cells in vitro and in in vivo model systems of disease are all used to gauge the translational potential of the therapeutic CAR structures generated.
This page was last updated on 3/5/2014.